On May 31, 2013 BeiGene and Merck KGaA reported that they have entered into a global licensing, co-development, and commercialization agreement for BeiGene-283 (Press release BeiGene, MAY 31, 2013, View Source [SID:1234500415]).
The compound is a second-generation BRAF inhibitor for the treatment of cancer. BeiGene-283, which is currently in preclinical development, was discovered and developed in the People’s Republic of China by BeiGene. It is expected to enter clinical development next year. BRAF inhibitors target a protein (BRAF) that is a downstream component of the MAPK pathway, which is thought to promote cancer cell growth and is dysregulated in a number of human cancers.
Under the terms of the collaboration, BeiGene will be responsible for the development and commercialization of BeiGene-283 in the People’s Republic of China and Merck KGaA will be responsible for the development and commercialization of BGB-283 for the rest of the world. BeiGene will receive an undisclosed upfront payment and is eligible to receive further payments of up to US$ 233 million for the achievement of clinical development and potential commercial milestones in both the People’s Republic of China and rest of the world, as well as up to double digit royalties on net sales.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!